IDH1 and acute myeloid leukemia: Vorasidenib (AG-881), a dual IDH1/2 inhibitor, prevents isoform switching; however, the study of vorasidenib in AML was discontinued due to its limited efficacy in patients with R/R AML in a phase 1 trial (NCT02492737) [107].